Topvision Berhad announced the launch of its prospectus for the upcoming Public Offering in conjunction with the transfer of listing from the LEAP Market to the ACE Market of Bursa Malaysia Securities Berhad.

The firm aims to raise RM17.89 million through the issuance of 54.22 million new ordinary shares at a retail price of RM0.33 per share. The funds raised will mainly be used for a new eye specialist centre, adding more eye care network and purchase of new equipments it said during the launch.

Dr. Peter Chong Kuok Siong, Chief Executive Officer and Executive Director of TOPVISION said, "We are thrilled to launch our prospectus, marking TOPVISION's another milestone in the process of transfer its listing to the ACE Market. This move not only accelerates our growth but underscores our commitment to advancing eye healthcare across Malaysia. With funds raised, we will expand our ACC network, establish TOPVISION International, and invest in new machines, all aimed at enhancing patient care. This listing reflects our dedication to sustainable growth, clinical excellence, and our mission to improve the quality of life for our patients."

The medical eye care industry in Malaysia is projected to grow significantly, with revenue expected to expand at a compound annual growth rate ("CAGR") of 10.0% from RM849.50 million in 2024 to RM1,249.40 million by 2028. This growth is driven by several key demand and supply factors. On the demand side, factors include steady population growth, an ageing population, increased medical tourism, growing consumer affluence, and a rise in lifestyle-related diseases. Meanwhile, supply-side growth is supported by advancements in medical eye care technology and strong government support.